SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China )
Also on site :
- The Best Way to Defrost Meat Quickly, According to Chefs & Food Safety Experts
- 55 Satisfying Vegan Breakfasts to Power Your Day
- Gaza war: Families accuse Netanyahu of sacrificing captives